https://scholars.lib.ntu.edu.tw/handle/123456789/528292
標題: | Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections | 作者: | Lin S.-Y. Huang C.-H. Ko W.-C. Chen Y.-H. PO-REN HSUEH |
公開日期: | 2016 | 卷: | 17 | 期: | 3 | 起(迄)頁: | 339-354 | 來源出版物: | Expert Opinion on Pharmacotherapy | 摘要: | Introduction: Treatment of complicated intra-abdominal infections (cIAIs) is becoming increasingly difficult because of the widespread emergence of multidrug-resistant organisms.Areas covered: In this review, we discuss the effectiveness of several new antibiotics for the treatment of cIAIs, including new β-lactamase inhibitor combinations (BLICs) and tetracycline-class drugs, recently developed aminoglycosides and quinolones, and novel lipoglycopeptides and oxazolidinones.Expert opinion: Of the new BLICs, ceftolozane/tazobactam is associated with adequate clinical cure rates in patients with cIAIs. Currently, two new β-lactamase inhibitors, namely avibactam and MK-7655, are under development for clinical use in the treatment of cIAIs. Eravacycline, a novel, fully synthetic tetracycline-class drug, has been shown in Phase II and III clinical trials to be more potent than tigecycline against a significant number of multidrug-resistant organisms causing cIAIs. Plazomicin, a next-generation aminoglycoside, is a promising agent for treatment of cIAIs due to multidrug-resistant pathogens. Of the recently developed quinolones, delafloxacin and finafloxacin have been shown to be effective against pathogens that survive and multiply in mildly acidic environments, although further clinical studies examining their clinical utility in the treatment of cIAIs are warranted. Oritavancin, a new semisynthetic lipoglycopeptide agent, has been demonstrated to be a potent antibiotic in the treatment of cIAIs due to drug-resistant Gram-positive organisms. Several other new antibiotics in development also show promise and will hopefully broaden the possibilities for treatment of complicated intra-abdominal infections due to MDR pathogens. ? 2015 Taylor & Francis. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/528292 | ISSN: | 1465-6566 | DOI: | 10.1517/14656566.2016.1122756 | SDG/關鍵字: | amikacin; antibiotic agent; avibactam; aztreonam; carbapenem derivative; ceftaroline; ceftazidime; ceftolozane; delafloxacin; eravacycline; ertapenem; finafloxacin; imipenem; oritavancin; oxazolidinone derivative; plazomicin; polypeptide antibiotic agent; relebactam; tazobactam; tigecycline; antiinfective agent; beta lactamase inhibitor; drug combination; abdominal infection; Acinetobacter; antibiotic resistance; Bacteroides fragilis; Candida; carbapenem resistant Pseudomonas aeruginosa; carbapenemase producing Enterobacteriaceae; drug efficacy; extended spectrum beta lactamase producing Escherichia coli; extended spectrum beta lactamase producing Klebsiella pneumoniae; hospital infection; infection risk; methicillin resistant Staphylococcus aureus; microbiology; mortality rate; multicenter study (topic); phase 1 clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); Pseudomonas aeruginosa; randomized controlled trial (topic); Review; Streptococcus; vancomycin resistant Enterococcus; antibiotic resistance; drug combination; Gram-Negative Bacterial Infections; human; Intraabdominal Infections; multidrug resistance; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacterial Infections; Humans; Intraabdominal Infections |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。